A Pilot Study of Risk-Guided Cardioprotection with Carvedilol

Recruiting

99 years or below

All

Phase 1

50 participants needed

1 Location

Brief description of study

Subjects with breast cancer starting treatment with anthracyclines/trastuzumab will be enrolled and their risk of cardiotoxicity calculated. If elevated risk, they will be randomized to intervention with carvedilol for 1 year vs usual care. Low risk subjects will be usual care. All subjects will be followed with serial echo, survey, and blood draws.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: breast cancer
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 832105

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Pilot Study of Risk-Guided Cardioprotection with Carvedilol in Breast Cancer Patients Treated with Doxorubicin and/or Trastuzumab

Brief description of study

Eligibility of study

Find a site

Interested in the study